UK-based HOX Therapeutics is aiming to add therapeutic options for glioma and prostate cancer patients with its lead candidate HTL001, a small peptide drug candidate that prevents the HOX gene from binding to a group of proteins called PBX (Pre-B-cell Leukaemia Homeobox). The company and its pipeline is based on the hypothesis that inhibiting HOX-PBX binding in a highly-targeted manner could result in new therapies.
The small company employs only five people so far, and is the first commercial enterprise to target the HOX gene...